Home Podcasts Frameshifts with Benjamin Arya
Frameshifts with Benjamin Arya

Frameshifts with Benjamin Arya

Benjamin Arya 28 Episodes Jul 5, 2026

Frameshifts with Benjamin Arya is a podcast spotlighting the world's most ambitious biotech founders, investors, researchers, and change-makers. Each episode features in-depth conversations with leaders driving innovation in biotechnology and related fields. The show explores the journeys, insights, and challenges of those shaping the future of biology and medicine. It aims to inspire and inform listeners interested in the cutting edge of biotech.

Episodes

Logan Thrasher Collins: The Trojan Horse That Could Fix Gene Therapy | Frameshifts Episode #14
Logan Thrasher Collins: The Trojan Horse That Could Fix Gene Therapy | Frameshifts Episode #14 Jul 5, 2026 3458 On this show, we’ve talked a lot about gene editors. These are little molecular machines derived from or inspired by the Nobel-prize winning CRISPR system that put gene editing on the radar of the general public.Once these editors get into a cell, they can cut out DNA, change the DNA sequence, insert entire copies of genes or delete faulty genes that cause illness. Think of them as tools to cut, p
Joe Betts-LaCroix on Retro, Reprogramming, and the First Real Longevity Drugs | Frameshifts Episode #13
Joe Betts-LaCroix on Retro, Reprogramming, and the First Real Longevity Drugs | Frameshifts Episode #13 Jun 20, 2026 4889 Most longevity talk is still stuck within two bad schools of thought. On one side, weak-sauce incrementalism: supplements, vibes and tiny effect sizes. On the other, immortality rhetoric that asks you to throw out the data altogether. Joe Betts-LaCroix has very little patience for either.He’s the co-founder and CEO of Retro Biosciences, one of the most ambitious longevity companies in the world. L
Alex Zhavoronkov: Beating Aging, Designing Drugs and Betting on China | Frameshifts Episode #12
Alex Zhavoronkov: Beating Aging, Designing Drugs and Betting on China | Frameshifts Episode #12 May 24, 2026 4809 Plenty of people will tell you AI is about to design our drugs. Alex Zhavoronkov already has. His company’s lead candidate, rentosertib, is the first drug with both its biological target and its molecule discovered by generative AI to post real Phase 2 results in humans. That gap, between the pitch deck and a drug in an actual person, is the whole reason this conversation is worth your time.Alex s
Building Science's Missing Infrastructure — Adam Marblestone | Frameshifts Episode #11
Building Science's Missing Infrastructure — Adam Marblestone | Frameshifts Episode #11 Apr 2, 2026 5117 Many of science’s most important projects fall through the cracks between academia and industry. These are the foundational tools that could accelerate entire fields, and yet don’t fit neatly into a PhD thesis or a venture-backed startup.And to humanity’s credit, there has been growing interest in the last few years in building alternative systems for accelerating science beyond academia and indus
Why 92% of Your Proteins Are Invisible — Parag Mallick | Frameshifts Episode #10
Why 92% of Your Proteins Are Invisible — Parag Mallick | Frameshifts Episode #10 Dec 17, 2025 4623 Parag Mallick is a Stanford Professor and Chief Scientist at Nautilus Biotechnology, a publicly traded biotech company. He’s also a professional magician and circus performer, which might sound random until you realize that his company does the closest thing to proteomics magic I’ve ever seen. The things that make you weird, he argues, are exactly what let you see data differently than anyone else
Building the Wyss Institute, Organs-on-Chips, and Fighting for Science — Don Ingber | Frameshifts Episode #9
Building the Wyss Institute, Organs-on-Chips, and Fighting for Science — Don Ingber | Frameshifts Episode #9 Dec 2, 2025 4592 The future of human biology isn’t about better animal models - it’s about building human organs on chips that think like the body does.Don Ingber, founding director of Harvard’s Wyss Institute, has one of the most unconventional origin stories in the field. In 1975, as a Yale undergrad, he took a sculpture class where students built floating structures held together only by tension; no rods touchi
Shelby Newsad: Why Platforms Fail, What Founders Need, and Where Biotech Wins | Frameshifts Episode #8
Shelby Newsad: Why Platforms Fail, What Founders Need, and Where Biotech Wins | Frameshifts Episode #8 Nov 25, 2025 3966 This week, I sat down with Shelby Newsad, Partner at Compound VC, to break down what makes a great biotech investment and why so many platform stories fall short.Shelby lays out a playbook forged across therapeutics, diagnostics, and lab automation. We dive into why mechanistic understanding predicts success, how diagnostics evolve into data businesses, and why the next wave of value may come from
Space Travel, AI, and Immortality — Peter Diamandis | Frameshifts Episode #7
Space Travel, AI, and Immortality — Peter Diamandis | Frameshifts Episode #7 Nov 18, 2025 4276 What happens when the man who launched commercial spaceflight decides humanity needs to stop aging?Peter Diamandis is building the infrastructure to tackle aging. He founded the XPRIZE Foundation, created Singularity University with Larry Page and Ray Kurzweil, and wrote the playbook on exponential thinking with Abundance and Bold. However, somewhere between flying Stephen Hawking into zero gravit
Minimally Invasive Neurosurgery, Brain-Computer Interfaces, and Continuous Pupil Monitoring — Theodore Schwartz
Minimally Invasive Neurosurgery, Brain-Computer Interfaces, and Continuous Pupil Monitoring — Theodore Schwartz Nov 11, 2025 5149 What happens when one of the world’s leading neurosurgeons steps away from the operating room to become a first-time founder? Dr. Theodore Schwartz pioneered minimally invasive brain surgery going through the nose and eyelid instead of opening the skull. He’s published over 200 papers, written a bestselling book on neurosurgery history, and now he’s building a MedTech startup to solve a problem th
Michael Florea: Smart Cages, AAV Cocktails & The Future of Longevity Research | Frameshifts Episode #5
Michael Florea: Smart Cages, AAV Cocktails & The Future of Longevity Research | Frameshifts Episode #5 Nov 4, 2025 4908 This week, I sat down with genome engineering prodigy Michael Florea.I first met Michael at the Longevity Biotech Fellowship retreat in Tahoe National Forest, California (2.5hrs east of SF). I was in the final days of building an AI edtech startup, and looking for advice on what to do next.Michael had been genetically engineering longevity since he was 16 years old. What he always wanted to do was
Virtual Cells, Programmable Biology, and the Quest to Hack Human Aging — Omar Abudayyeh & Jonathan Gootenberg
Virtual Cells, Programmable Biology, and the Quest to Hack Human Aging — Omar Abudayyeh & Jonathan Gootenberg Oct 9, 2025 5081 This week, I sat down with Omar Abudayyeh and Jonathan Gootenberg, the co-PIs who helped pioneer the field of genome engineering, and are now leading one of the most innovative and productive bioengineering labs in the world.Omar and Jonathan met as graduate students in the lab of CRISPR pioneer, Feng Zhang. They have since co-authored more than 30 breakthrough papers that helped transform CRISPR-
Francisco LePort & Martin Borch Jensen: The Biotech Founders Testing 25 Drugs in One Horse | Frameshifts Episode #3
Francisco LePort & Martin Borch Jensen: The Biotech Founders Testing 25 Drugs in One Horse | Frameshifts Episode #3 Oct 1, 2025 4864 In this week’s episode, I sit down with Francisco LePort and Martin Borch Jensen, the co-founders of Gordian Biotechnology. Gordian is revolutionizing drug discovery by testing where it matters most… directly in living organisms. We discuss their groundbreaking approach of pooled in vivo screening that transforms a single organism into thousands of parallel experiments, and how this could fundamen

Recommended